Cargando…
Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe
INTRODUCTION: Additional risk minimisation measures (aRMMs) may be required to minimise important risks of medicines. aRMMs may be required at the time of authorisation, but may also be introduced or discontinued during the product life cycle as new safety information arises. The aim of this study i...
Autores principales: | Francisca, Reynold D. C., Baba, Emna, Hoeve, Christina E., Zomerdijk, Inge M., Sturkenboom, Miriam C. J. M., Straus, Sabine M. J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813721/ https://www.ncbi.nlm.nih.gov/pubmed/33000427 http://dx.doi.org/10.1007/s40264-020-00993-6 |
Ejemplares similares
-
Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union
por: Hoeve, Christina E., et al.
Publicado: (2019) -
Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021
por: Essink, Sharon C. M., et al.
Publicado: (2023) -
Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe
por: Mayall, Steve, et al.
Publicado: (2021) -
Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors
por: Hoeve, Christina E., et al.
Publicado: (2020) -
Isotretinoin exposure during pregnancy: a population-based study in The Netherlands
por: Zomerdijk, Ingeborg M, et al.
Publicado: (2014)